Roche (SWX: ROG) and Alnylam (NASDAQ: ALNY) have announced that a Phase II trial for their RNAi therapeutic, zilebesiran, has successfully met its primary endpoint of significantly reducing 24-hour mean systolic blood pressure (SBP) at month three in patients with mild-to-moderate hypertension. The results also demonstrated reductions in SBP and angiotensinogen (AGT) after six months, along with encouraging safety and tolerability data.
Potential for Quarterly or Biannual Dosing
According to the press release, the study indicates the potential for the subcutaneous injection of zilebesiran to control blood pressure with dosing intervals of either quarterly or biannual, offering a novel approach to hypertension management.
Partnership for Zilebesiran Development
Roche and Alnylam entered into a partnership this year to develop zilebesiran, with the program including another ongoing Phase II study that combines the therapy with anti-hypertensives. This collaboration aims to explore the full potential of RNAi therapeutics in the treatment of hypertension and other conditions.-Fineline Info & Tech
